论文部分内容阅读
多发性骨髓瘤(MM)是一种较常见的浆细胞增生性血液肿瘤,发病率占恶性肿瘤的1%左右,占恶性血液病的10%左右[1]。多见于中老年人,多次化疗后易产生耐药,而发展为难治性复发性MM。血管生成抑制药沙利度胺是一种谷氨酸衍生物,曾作为非巴比妥类催眠药应用,后因其致畸作用而被禁用。近年来,沙利度胺用于治疗难治性MM取得了一定进展。2009年3月-2010年12月,我们采用沙利度胺治疗难治性MM 45例,疗效较好。现分析报告如下。
Multiple myeloma (MM) is a more common plasma cell hyperplasia hematological malignancy, the incidence of about 1% of malignant tumors, accounting for about 10% of hematological malignancies [1]. More common in the elderly, multiple chemoresistance prone to drug resistance, and the development of refractory recurrent MM. Thalidomide, an angiogenesis inhibitor, is a glutamate derivative that has been banned as a non-barbiturative hypnotic and later used as a teratogen. In recent years, thalidomide for the treatment of refractory MM has made some progress. March 2009 - December 2010, we use thalidomide refractory MM 45 cases, the better effect. The analysis report is as follows.